Atricure reports preliminary results for fourth quarter and full year 2022, provides financial outlook for 2023

Mason, ohio--( business wire )--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2022 and provided 2023 financial guidance.
ATRC Ratings Summary
ATRC Quant Ranking